

Domingo Francisco Javier DÃ- ez MartÃ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4030711/publications.pdf>

Version: 2024-02-01

308
papers

19,354
citations

8755

77
h-index

17891

125
g-index

326
all docs

326
docs citations

326
times ranked

21072
citing authors

#	ARTICLE	IF	CITATIONS
1	Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 817-824.	0.4	15
2	Management of cardiac fibrosis is the largest unmet medical need in heart failure. <i>Cardiovascular Research</i> , 2022, 118, e20-e22.	1.8	23
3	Transition to heart failure in hypertension: going to the heart of the matter. <i>European Heart Journal</i> , 2022, 43, 3332-3334.	1.0	6
4	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. <i>European Journal of Heart Failure</i> , 2022, 24, 321-331.	2.9	16
5	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 865-872.	1.4	16
6	MO747: Endotrophin Levels are Extremely Elevated in Dialysis Patients with Heart Failure with Preserved Ejection Fraction (HFPEF) and are Influenced by Background Treatment with Diuretics and ARBS/ACEI. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
7	A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. <i>Cancers</i> , 2022, 14, 2941.	1.7	4
8	The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1559-1568.	2.9	12
9	Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness. <i>Diabetes Care</i> , 2021, 44, 224-230.	4.3	20
10	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. <i>Nature Reviews Cardiology</i> , 2021, 18, 479-498.	6.1	128
11	The need for a cardioneurology subspecialty. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1491-1494.	1.4	12
12	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. <i>JACC: Heart Failure</i> , 2021, 9, 268-277.	1.9	46
13	MO734CONTRIBUTION OF SOLUBLE ST2 TO THE EFFECT OF RIGHT VENTRICULAR DYSFUNCTION ON MORTALITY IN HEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
14	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1875-1887.	2.9	37
15	Bases para la creación de las unidades clínicas cardiorrenales. Documento de consenso de los grupos de trabajo cardiorrenal de la SEC y la SEN. <i>REC: CardioClinics</i> , 2021, 56, 284-295.	0.1	8
16	Heart failure-related skeletal myopathy. Potential involvement of myokines. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 1008-1012.	0.4	1
17	The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy—multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 933-944.	2.9	34
18	Identification of sex-specific biomarkers predicting new-onset heart failure. <i>ESC Heart Failure</i> , 2021, 8, 3512-3520.	1.4	11

#	ARTICLE	IF	CITATIONS
19	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2021, 41, 391-402.	0.2	3
20	Miopatía esclerótica en la insuficiencia cardiaca. Implicación potencial de las miocinas. <i>Revista Española De Cardiología</i> , 2021, 74, 1009-1009.	0.6	0
21	Deficiency of Procollagen C-Proteinase Enhancer 1 in Mice has No Major Impact on Cardiac Collagen and Function Under Basal Conditions. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, e703-e713.	0.8	4
22	Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension. <i>JACC Basic To Translational Science</i> , 2021, 6, 12-21.	1.9	28
23	Serum and urinary biomarkers of collagen type I turnover predict prognosis in patients with heart failure. <i>Clinical and Translational Medicine</i> , 2021, 11, e267.	1.7	10
24	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart OMICS™ in AGEing (HOMAGE) randomized clinical trial. <i>European Heart Journal</i> , 2021, 42, 684-696.	1.0	77
25	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 754499.	1.1	30
26	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2021, 41, 391-402.	0.2	3
27	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses. <i>Clinical Research in Cardiology</i> , 2020, 109, 22-33.	1.5	19
28	Reprint of "The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking". <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118521.	1.9	7
29	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. <i>Nefrologia</i> , 2020, 40, 223-236.	0.2	21
30	Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. <i>Revista Española De Cardiología (English Ed)</i> , 2020, 73, 248-254.	0.4	4
31	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. <i>Nefrologia</i> , 2020, 40, 223-236.	0.2	7
32	Role of Cardiac Lymphatics in Myocardial Edema and Fibrosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 735-744.	1.2	45
33	Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease. <i>Journal of Hypertension</i> , 2020, 38, 2036-2042.	0.3	17
34	Hypertrophic cardiomyopathy in myosin-binding protein C (<i>MYBPC3</i>) Icelandic founder mutation carriers. <i>Open Heart</i> , 2020, 7, e001220.	0.9	10
35	Does Chronic Kidney Disease Facilitate Malignant Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction of Hypertensive Origin?. <i>Journal of Clinical Medicine</i> , 2020, 9, 404.	1.0	15
36	Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study. <i>Diabetologia</i> , 2020, 63, 1043-1054.	2.9	18

#	ARTICLE	IF	CITATIONS
37	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. <i>Circulation</i> , 2020, 141, 751-767.	1.6	48
38	Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 835-843.	0.4	5
39	Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2204-2218.	1.2	63
40	La fibrosis intersticial miocárdica en la era de la medicina de precisión. El fenotipado basado en biomarcadores para un tratamiento personalizado. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 248-254.	0.6	8
41	Myocardial fibrosis as a matter of cell differentiation: opportunities for new antifibrotic strategies. <i>European Heart Journal</i> , 2019, 40, 979-981.	1.0	7
42	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. <i>Heart</i> , 2019, 105, 307-314.	1.2	28
43	Why Clinicians Should Care About the Cardiac Interstitium. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2305-2318.	2.3	20
44	Biomarkers of Cardiovascular Disease. , 2019, , 319-330.		0
45	Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease. <i>Hypertension</i> , 2019, 73, 820-828.	1.3	41
46	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 272-285.	2.9	182
47	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005897.	1.6	63
48	The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 1421-1432.	1.9	50
49	Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 1231-1240.	0.8	8
50	Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1398-1410.	1.2	54
51	The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1016-1025.	1.2	52
52	Cardioprotective Effect of the Mitochondrial Unfolded Protein Response During Chronic Pressure Overload. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1795-1806.	1.2	97
53	Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic banding-induced chronic pressure overload. <i>Scientific Reports</i> , 2019, 9, 2956.	1.6	11
54	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. <i>Hypertension</i> , 2019, 73, 602-611.	1.3	78

#	ARTICLE	IF	CITATIONS
55	Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population. <i>Journal of the American Heart Association</i> , 2019, 8, e010430.	1.6	5
56	Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both?. <i>American Journal of Hypertension</i> , 2019, 32, 15-17.	1.0	3
57	The renal immune-inflammatory component of arterial hypertension: emerging therapeutic strategies. <i>Cardiovascular Research</i> , 2019, 115, 696-698.	1.8	2
58	Aging and atrial fibrillation: a matter of fibrosis. <i>Aging</i> , 2019, 11, 9965-9966.	1.4	16
59	Myocardial Interstitial Fibrosis in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1696-1706.	1.2	406
60	Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 860-871.	1.2	266
61	Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. <i>European Heart Journal</i> , 2018, 39, 699-709.	1.0	178
62	MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure. <i>Hypertension</i> , 2018, 71, 280-288.	1.3	128
63	Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1290-1299.	2.9	64
64	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. <i>European Heart Journal</i> , 2018, 39, 2793-2799.	1.0	26
65	Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. <i>Matrix Biology</i> , 2018, 66, 110-124.	1.5	39
66	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. <i>ESC Heart Failure</i> , 2018, 5, 139-148.	1.4	21
67	Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). <i>European Journal of Heart Failure</i> , 2018, 20, 460-470.	2.9	29
68	Sex Dimorphism in the Myocardial Response to Aortic Stenosis. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 962-973.	2.3	85
69	Myocardial Remodeling in Hypertension. <i>Hypertension</i> , 2018, 72, 549-558.	1.3	123
70	Immunomodulation by adoptive regulatory T cell transfer improves Cocksackievirus B3-induced myocarditis. <i>FASEB Journal</i> , 2018, 32, 6066-6078.	0.2	42
71	Unraveling New Mechanisms of Renal Fibrosis With Potential Therapeutic Implications. <i>Hypertension</i> , 2018, 72, 277-278.	1.3	1
72	Reply. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2984-2985.	1.2	0

#	ARTICLE	IF	CITATIONS
73	Role of Myocardial Collagen in Severe Aortic Stenosis With Preserved Ejection Fraction and Symptoms of Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 832-840.	0.4	18
74	Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. <i>Scientific Reports</i> , 2017, 7, 41865.	1.6	21
75	Myocardial fibrosis: biomedical research from bench to bedside. <i>European Journal of Heart Failure</i> , 2017, 19, 177-191.	2.9	280
76	MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. <i>Scientific Reports</i> , 2017, 7, 40696.	1.6	39
77	Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2017, 113, 906-914.	1.8	20
78	Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men. <i>Free Radical Research</i> , 2017, 51, 389-396.	1.5	18
79	Risk for Incident Heart Failure: A Subjectâ€Level Metaâ€Analysis From the Heart â€œOMicsâ€in AGEing (HOMAGE) Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	41
80	Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. <i>Journal of Hypertension</i> , 2017, 35, 853-861.	0.3	58
81	Myocardial fibrosis in response to pressure overload: elucidating the contribution of tissue transglutaminase. <i>Cardiovascular Research</i> , 2017, 113, 841-843.	1.8	5
82	A Urinary Fragment of Mucin-1 Subunit 1± Is a Novel Biomarker Associated With Renal Dysfunction in the General Population. <i>Kidney International Reports</i> , 2017, 2, 811-820.	0.4	24
83	Epicardial Adipose Tissue in the General Middle-aged Population and Its Association With Metabolic Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 254-260.	0.4	15
84	Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients â€60 Years With Heart Failure and Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2017, 119, 2042-2048.	0.7	24
85	Papel del colÃ¡geno miocÃ¡rdico en la estenosis aÃ³rtica grave conÂfracciÃ³n deÂeyecciÃ³n conservada yÃ¡sÃ¡ntomas deÂinsuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 832-840.	0.6	26
86	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 995.	3.0	164
87	Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling. <i>Scientific Reports</i> , 2017, 7, 16042.	1.6	37
88	Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. <i>Open Heart</i> , 2017, 4, e000615.	0.9	22
89	Compelling Benefit of Soluble Suppression of Tumorigenicityâ€2 in Postâ€Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	7
90	The Hypertensive Myocardium. <i>Medical Clinics of North America</i> , 2017, 101, 43-52.	1.1	21

#	ARTICLE	IF	CITATIONS
91	Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 167-176.	2.9	91
92	Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients. <i>Journal of Hypertension</i> , 2016, 34, 130-138.	0.3	30
93	What is on the horizon for improved treatments for acutely decompensated heart failure?. <i>European Heart Journal Supplements</i> , 2016, 18, G33-G42.	0.0	0
94	Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. <i>Nature Communications</i> , 2016, 7, 13710.	5.8	190
95	Understanding the Role of CCN Matricellular Proteins in Myocardial Fibrosis —. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1569-1571.	1.2	4
96	Targeting the Cardiac Myofibroblast Secretome to Treat Myocardial Fibrosis in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	19
97	Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients. <i>Clinical Science</i> , 2016, 130, 2139-2149.	1.8	12
98	Myocardial Collagen Cross-Linking Is Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 251-260.	1.2	127
99	Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 119-130.	1.4	21
100	DPP-4 inhibition and blood pressure lowering in perspective. <i>Journal of Hypertension</i> , 2016, 34, 184-187.	0.3	4
101	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. <i>PLoS ONE</i> , 2016, 11, e0167582.	1.1	22
102	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. <i>European Journal of Heart Failure</i> , 2015, 17, 764-771.	2.9	109
103	Targeting β -secretases protect against angiotensin II-induced cardiac hypertrophy. <i>Journal of Hypertension</i> , 2015, 33, 843-850.	0.3	9
104	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	174
105	Diltiazem Treatment for Pre-Clinical Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers. <i>JACC: Heart Failure</i> , 2015, 3, 180-188.	1.9	137
106	Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: A pilot study. <i>Free Radical Biology and Medicine</i> , 2015, 81, 1-12.	1.3	27
107	Circulating Biomarkers of Myocardial Fibrosis. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2449-2456.	1.2	196
108	Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. <i>European Journal of Heart Failure</i> , 2015, 17, 385-392.	2.9	54

#	ARTICLE	IF	CITATIONS
109	Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study. <i>International Journal of Cardiology</i> , 2015, 185, 177-185.	0.8	31
110	“Targeting the Heart” in Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 661-669.	1.9	50
111	El tratamiento de la insuficiencia cardíaca con fracción de eyección preservada. Un problema sin resolver. <i>Revista Clínica Española</i> , 2015, 215, 320-321.	0.2	2
112	<i>microRNA-122</i> down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF- β 1 up-regulation. <i>Clinical Science</i> , 2014, 126, 497-506.	1.8	80
113	Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease. <i>Hypertension</i> , 2014, 63, 468-474.	1.3	16
114	Association of Cardiotrophin-1 With Myocardial Fibrosis in Hypertensive Patients With Heart Failure. <i>Hypertension</i> , 2014, 63, 483-489.	1.3	48
115	Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 463-469.	0.6	26
116	Cooperative Research in Biomedicine. Spain's Cardiovascular Network, Red de Investigación Cardiovascular. <i>Revista Española De Cardiología (English Ed)</i> , 2014, 67, 254-258.	0.4	1
117	Arterial Hypertension in Patients with Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 233-242.	1.0	16
118	Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. <i>Biomaterials</i> , 2014, 35, 143-151.	5.7	90
119	Downregulation of G protein-coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on cardioprotective gene expression patterns. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 2448-2456.	1.8	38
120	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014, 35, 2797-2815.	1.0	304
121	Atrial fibrillation and biomarkers of myocardial fibrosis in heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2014, 48, 299-303.	0.4	17
122	Serelaxin: A Novel Therapy for Acute Heart Failure with a Range of Hemodynamic and Non-Hemodynamic Actions. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 275-285.	1.0	25
123	Heart “omics”™ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , 2014, 28, 349.	0.7	24
124	The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2013, 12, 143.	2.7	24
125	T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 415-422.	1.3	195
126	A Synthetic Peptide from Transforming Growth Factor- β 1 Type III Receptor Inhibits NADPH Oxidase and Prevents Oxidative Stress in the Kidney of Spontaneously Hypertensive Rats. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 1607-1618.	2.5	21

#	ARTICLE	IF	CITATIONS
127	Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model. <i>Circulation: Heart Failure</i> , 2013, 6, 1239-1249.	1.6	241
128	Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?. <i>Cardiovascular Research</i> , 2013, 99, 111-120.	1.8	113
129	Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis. <i>Clinical Science</i> , 2013, 125, 291-300.	1.8	14
130	Absence of Cardiotrophin 1 Is Associated With Decreased Age-Dependent Arterial Stiffness and Increased Longevity in Mice. <i>Hypertension</i> , 2013, 61, 120-129.	1.3	42
131	Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. <i>Journal of Hypertension</i> , 2013, 31, 587-594.	0.3	17
132	Cardiotrophin 1 Is Involved in Cardiac, Vascular, and Renal Fibrosis and Dysfunction. <i>Hypertension</i> , 2012, 60, 563-573.	1.3	55
133	Collagen Cross-Linking But Not Collagen Amount Associates With Elevated Filling Pressures in Hypertensive Patients With Stage C Heart Failure. <i>Hypertension</i> , 2012, 60, 677-683.	1.3	170
134	Cardiotrophin-1 induces sarcoplasmic reticulum Ca ²⁺ leak and arrhythmogenesis in adult rat ventricular myocytes. <i>Cardiovascular Research</i> , 2012, 96, 81-89.	1.8	22
135	Contribution of circulating biomarkers to unravel the role of extracellular matrix in hypertensive cardiac remodelling. <i>Journal of Hypertension</i> , 2012, 30, 34-37.	0.3	2
136	Péptido similar al glucagón tipo 1 y supervivencia de la célula cardiaca. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2012, 59, 561-569.	0.8	8
137	Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. <i>Cardiovascular Ultrasound</i> , 2012, 10, 10.	0.5	68
138	Blockade of TGF- β 1 Signalling Inhibits Cardiac NADPH Oxidase Overactivity in Hypertensive Rats. <i>Oxidative Medicine and Cellular Longevity</i> , 2012, 2012, 1-8.	1.9	14
139	GLP-1 and cardioprotection: from bench to bedside. <i>Cardiovascular Research</i> , 2012, 94, 316-323.	1.8	93
140	The influence of obesity on the assessment of carotid intima-media thickness. <i>Journal of Clinical Ultrasound</i> , 2012, 40, 479-485.	0.4	7
141	Cardiotrophin-1 in hypertensive heart disease. <i>Endocrine</i> , 2012, 42, 9-17.	1.1	22
142	New Targets to Treat the Structural Remodeling of the Myocardium. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1833-1843.	1.2	147
143	Association of the peroxisome proliferator-activated receptor α gene L162V polymorphism with stage C heart failure. <i>Journal of Hypertension</i> , 2011, 29, 876-883.	0.3	8
144	Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. <i>Journal of Hypertension</i> , 2011, 29, 17-26.	0.3	64

#	ARTICLE	IF	CITATIONS
145	Towards the molecular diagnosis of hypertensive heart disease?. Journal of Hypertension, 2011, 29, 660-662.	0.3	1
146	Altered regulation of the epithelial sodium channel in hypertension. From genes to therapeutics. Journal of Hypertension, 2011, 29, 204-206.	0.3	0
147	Aspectos emergentes del sistema renina-angiotensina en la diabetes: ¿cómo abordar su traslación a la clínica?. Revista Espanola De Cardiologia Suplementos, 2011, 11, 37-41.	0.2	0
148	Urinary proteomics in cardiovascular disease: Achievements, limits and hopes. Proteomics - Clinical Applications, 2011, 5, 222-232.	0.8	11
149	Angiotensin II and Myocardial Remodeling: Do Macrophages Hold the Key?. American Journal of Hypertension, 2011, 24, 626-627.	1.0	0
150	HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. Cardiovascular Research, 2011, 92, 247-255.	1.8	42
151	Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. European Heart Journal, 2011, 32, 177-183.	1.0	26
152	Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1361-H1372.	1.5	70
153	A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H2372-H2382.	1.5	56
154	The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes. Frontiers in Bioscience - Elite, 2011, E3, 1467-1474.	0.9	5
155	Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension. Journal of Hypertension, 2010, 28, 2219-2226.	0.3	6
156	Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications. Journal of Hypertension, 2010, 28, 1944-1950.	0.3	44
157	Myocardial remodeling after infarction: the role of myofibroblasts. Nature Reviews Cardiology, 2010, 7, 30-37.	6.1	612
158	Corrigendum to "Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension" [FEBS Lett. 542 (2003) 27-31]. FEBS Letters, 2010, 584, 4709-4709.	1.3	0
159	Is the Deficiency of the Long Isoform of Cellular FLICE-Inhibitory Protein Involved in Myocardial Remodeling?. Hypertension, 2010, 56, 1045-1046.	1.3	1
160	Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1-H9.	1.5	209
161	Filling Pressures and Collagen Metabolism in Hypertensive Patients With Heart Failure and Normal Ejection Fraction. Hypertension, 2010, 55, 1418-1424.	1.3	100
162	A Translational Approach to Hypertensive Heart Disease. Hypertension, 2010, 55, 1-8.	1.3	98

#	ARTICLE	IF	CITATIONS
163	Association Between Left Ventricular Mass and Telomere Length in a Population Study. <i>American Journal of Epidemiology</i> , 2010, 172, 440-450.	1.6	53
164	G Protein-coupled Receptor Kinase 2 Plays a Relevant Role in Insulin Resistance and Obesity. <i>Diabetes</i> , 2010, 59, 2407-2417.	0.3	99
165	Altered degradation of extracellular matrix in myocardial remodelling: the growing role of cathepsins and cystatins. <i>Cardiovascular Research</i> , 2010, 87, 591-592.	1.8	20
166	Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. <i>Cardiovascular Research</i> , 2010, 88, 304-313.	1.8	25
167	Circulating Biomarkers of Collagen Metabolism in Cardiac Diseases. <i>Circulation</i> , 2010, 121, 1645-1654.	1.6	195
168	Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy. <i>New England Journal of Medicine</i> , 2010, 363, 552-563.	13.9	566
169	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. <i>Kidney International</i> , 2010, 78, 1275-1280.	2.6	37
170	Vascular effects of cardiotrophin-1: a role in hypertension?. <i>Journal of Hypertension</i> , 2010, 28, 1261-1272.	0.3	28
171	Do microRNAs regulate myocardial fibrosis?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 88-89.	3.3	10
172	Losartan Metabolite EXP3179 Blocks NADPH Oxidase-Mediated Superoxide Production by Inhibiting Protein Kinase C. <i>Hypertension</i> , 2009, 54, 744-750.	1.3	62
173	Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. <i>Cardiovascular Research</i> , 2009, 83, 586-594.	1.8	55
174	Prevalence of Left Ventricular Diastolic Dysfunction in a General Population. <i>Circulation: Heart Failure</i> , 2009, 2, 105-112.	1.6	291
175	Impact of Treatment on Myocardial Lysyl Oxidase Expression and Collagen Cross-Linking in Patients With Heart Failure. <i>Hypertension</i> , 2009, 53, 236-242.	1.3	144
176	Insulin-induced NADPH oxidase activation promotes proliferation and matrix metalloproteinase activation in monocytes/macrophages. <i>Free Radical Biology and Medicine</i> , 2009, 46, 1058-1067.	1.3	40
177	TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 897-904.	0.6	15
178	Towards a New Paradigm About Hypertensive Heart Disease. <i>Medical Clinics of North America</i> , 2009, 93, 637-645.	1.1	36
179	Genomics and Proteomics in Heart Failure Research. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 305-313.	0.4	4
180	Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients. <i>Journal of Hypertension</i> , 2009, 27, 1420-1430.	0.3	13

#	ARTICLE	IF	CITATIONS
181	Obesity-related cardiac and vascular structural alterations: beyond blood pressure overload. <i>Journal of Hypertension</i> , 2009, 27, 1750-1752.	0.3	12
182	The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. <i>Clinical Science</i> , 2009, 116, 233-240.	1.8	8
183	Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: Potential diagnostic implications. <i>Journal of Hypertension</i> , 2009, 27, 418-424.	0.3	45
184	Renin-Ângiotensin-Âldosterone System and Cardiomyocyte Apoptosis in Hypertensive Heart Disease. , 2009, , 143-150.		1
185	Left Ventricular Hypertrophy and Treatment with Renin Angiotensin System Inhibition. , 2009, , 103-119.		3
186	Cooperative Cardiovascular Disease Research Network (RECAVA). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 58-65.	0.4	8
187	Efecto vasodilatador de la ghrelina en la aorta de rata. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2008, 55, 448-453.	0.8	5
188	Serum Soluble ST2 as a Biochemical Marker of Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1466-1467.	1.2	22
189	Fibrosis. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2029-2031.	1.2	41
190	Overexpression of human truncated peroxisome proliferator-activated receptor α induces apoptosis in HL-1 cardiomyocytes. <i>Cardiovascular Research</i> , 2008, 79, 458-463.	1.8	11
191	Molecular Mechanisms of Atherosclerosis in Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 2187-2194.	1.1	51
192	A translational approach to myocardial remodelling. <i>Cardiovascular Research</i> , 2008, 81, 409-411.	1.8	8
193	Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy. <i>European Heart Journal</i> , 2008, 29, 898-906.	1.0	27
194	Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 294, E52-E60.	1.8	64
195	AT ₁ receptor antagonism attenuates target organ effects of salt excess in SHR without affecting pressure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 294, H853-H858.	1.5	82
196	Effects of Aldosterone on the Heart. <i>Hypertension</i> , 2008, 52, 462-464.	1.3	17
197	A synthetic peptide from transforming growth factor- β type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. <i>Cardiovascular Research</i> , 2008, 81, 601-609.	1.8	89
198	Myocardial fibrosis in chronic kidney disease: potential benefits of torsemide. <i>Kidney International</i> , 2008, 74, S19-S23.	2.6	54

#	ARTICLE	IF	CITATIONS
199	Biochemical markers of myocardial remodelling in hypertensive heart disease. <i>Cardiovascular Research</i> , 2008, 81, 509-518.	1.8	73
200	Aldosterone Induces Cardiotrophin-1 Expression in HL-1 Adult Cardiomyocytes. <i>Endocrinology</i> , 2008, 149, 4970-4978.	1.4	39
201	The Proinflammatory Mediator CD40 Ligand Is Increased in the Metabolic Syndrome and Modulated by Adiponectin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2319-2327.	1.8	33
202	Mechanical dyssynchrony: another mechanism of left ventricular dysfunction in hypertension?. <i>Journal of Hypertension</i> , 2008, 26, 399-402.	0.3	0
203	Diagnosis and Treatment of Myocardial Fibrosis in Hypertensive Heart Disease. <i>Circulation Journal</i> , 2008, 72, A8-A12.	0.7	20
204	NADPH oxidase <i>CYBA</i> polymorphisms, oxidative stress and cardiovascular diseases. <i>Clinical Science</i> , 2008, 114, 173-182.	1.8	90
205	Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?. <i>Cardiovascular Research</i> , 2007, 75, 536-545.	1.8	36
206	Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. <i>European Heart Journal</i> , 2007, 28, 2785-2791.	1.0	37
207	Association of Increased Plasma Cardiotrophin-1 With Inappropriate Left Ventricular Mass in Essential Hypertension. <i>Hypertension</i> , 2007, 50, 977-983.	1.3	44
208	Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 587-593.	1.1	82
209	The Role of Myocardial Collagen Network in Hypertensive Heart Disease. <i>Current Hypertension Reviews</i> , 2007, 3, 1-7.	0.5	5
210	Telomere dysfunction in hypertension. <i>Journal of Hypertension</i> , 2007, 25, 2185-2192.	0.3	49
211	A novel CYBA variant, the "675A/T polymorphism, is associated with essential hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1620-1626.	0.3	34
212	Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. <i>Journal of Hypertension</i> , 2007, 25, 2148-2157.	0.3	44
213	Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). <i>Journal of Hypertension</i> , 2007, 25, 1958-1966.	0.3	95
214	Mechanisms of Cardiac Fibrosis in Hypertension. <i>Journal of Clinical Hypertension</i> , 2007, 9, 546-550.	1.0	183
215	The Inhibitory Effect of Leptin on Angiotensin II-Induced Vasoconstriction in Vascular Smooth Muscle Cells Is Mediated via a Nitric Oxide-Dependent Mechanism. <i>Endocrinology</i> , 2007, 148, 324-331.	1.4	110
216	Identification of a Potential Cardiac Antifibrotic Mechanism of Torasemide in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 859-867.	1.2	118

#	ARTICLE	IF	CITATIONS
217	Oxidative Stress, Endothelial Dysfunction and Cerebrovascular Disease. <i>Cerebrovascular Diseases</i> , 2007, 24, 24-29.	0.8	65
218	Hypertensive Heart Disease. , 2007, , 621-631.		2
219	Avances en cardiopatía hipertensiva. Mecanismos de remodelado implicados en la transición de la hipertrofia a la insuficiencia cardiaca. <i>Revista Espanola De Cardiologia Suplementos</i> , 2007, 7, 14F-21F.	0.2	0
220	Highlights from International Congress. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 61-72.	1.0	0
221	C-Reactive Protein Induces Matrix Metalloproteinase-1 and -10 in Human Endothelial Cells. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1369-1378.	1.2	168
222	Alterations in the Pattern of Collagen Deposition May Contribute to the Deterioration of Systolic Function in Hypertensive Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 48, 89-96.	1.2	214
223	A Biomarker of Myocardial Fibrosis Predicts Long-Term Response to Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2335-2337.	1.2	18
224	Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. <i>Clinical Therapeutics</i> , 2006, 28, 832-848.	1.1	29
225	Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 41, 902-913.	0.9	43
226	Angiotensin II and Myocardial Fibrosis, Clinical Implications. , 2006, , 193-213.		0
227	Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study. <i>Journal of Hypertension</i> , 2006, 24, 395-402.	0.3	33
228	The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2006, 24, 1589-1597.	0.3	37
229	Apoptosis in hypertensive heart disease: a clinical approach. <i>Current Opinion in Cardiology</i> , 2006, 21, 288-294.	0.8	23
230	The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. <i>Journal of Hypertension</i> , 2006, 24, 1299-1306.	0.3	83
231	Arterial Stiffness and Extracellular Matrix. , 2006, 44, 76-95.		71
232	Oxidative stress and atherosclerosis in early chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2686-2690.	0.4	68
233	Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. <i>Cardiovascular Research</i> , 2006, 69, 899-907.	1.8	46
234	Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 290, H1503-H1509.	1.5	70

#	ARTICLE	IF	CITATIONS
235	Phagocytic NADPH Oxidase Overactivity Underlies Oxidative Stress in Metabolic Syndrome. <i>Diabetes</i> , 2006, 55, 209-215.	0.3	121
236	Remodeling in Hypertensive Heart Disease: Role of the Renin-Angiotensin-Aldosterone System. , 2006, , 177-189.		0
237	The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. <i>Journal of Hypertension</i> , 2005, 23, 1445-1451.	0.3	65
238	Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. <i>Journal of Hypertension</i> , 2005, 23, 625-632.	0.3	72
239	New directions in the assessment and treatment of hypertensive heart disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 428-434.	1.0	13
240	Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. <i>Journal of Hypertension</i> , 2005, 23, 2297-2304.	0.3	42
241	Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. <i>Kidney International</i> , 2005, 68, S71-S75.	2.6	45
242	Oxidative stress and vascular remodelling. <i>Experimental Physiology</i> , 2005, 90, 457-462.	0.9	129
243	NADPH Oxidase-dependent Superoxide Production Is Associated With Carotid Intima-Media Thickness in Subjects Free of Clinical Atherosclerotic Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1452-1457.	1.1	62
244	Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. <i>European Heart Journal</i> , 2005, 26, 153-158.	1.0	42
245	NADPH Oxidase-Mediated Oxidative Stress: Genetic Studies of the p22phox Gene in Hypertension. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 1327-1336.	2.5	86
246	Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. <i>Cytokine</i> , 2005, 30, 282-292.	1.4	45
247	Serum Markers of Fibrillar Collagen Metabolism in Cardiac Diseases. , 2005, , 101-113.		0
248	Mechanisms of Disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 209-216.	3.3	143
249	Profibrotic Effects of Angiotensin II in the Heart. <i>Hypertension</i> , 2004, 43, 1164-1165.	1.3	21
250	Generation of eight adjacent mutations in a single step using a site-directed mutagenesis kit. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 384-6.	1.4	6
251	Surrogate Markers for Cardiovascular Disease: Structural Markers. <i>Circulation</i> , 2004, 109, IV-22-IV-30.	1.6	175
252	Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis. <i>Circulation</i> , 2004, 110, 552-557.	1.6	157

#	ARTICLE	IF	CITATIONS
253	Functional Effect of the p22 phox Δ 930 A/G Polymorphism on p22 phox Expression and NADPH Oxidase Activity in Hypertension. <i>Hypertension</i> , 2004, 44, 163-169.	1.3	89
254	Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin. <i>Circulation</i> , 2004, 110, 1263-1268.	1.6	392
255	Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. <i>Medical Clinics of North America</i> , 2004, 88, 83-97.	1.1	83
256	Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2028-2035.	1.2	248
257	Peroxisome Proliferator-Activated Receptor γ and Hypertensive Heart Disease. <i>Drugs</i> , 2004, 64, 9-18.	4.9	19
258	Angiotensin II and the hypertensive heart. <i>Journal of Hypertension</i> , 2004, 22, 879-882.	0.3	5
259	Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 197-204.	1.0	40
260	Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. <i>Journal of Hypertension</i> , 2004, 22, 2169-2175.	0.3	92
261	Preliminary characterisation of the promoter of the human p22phox gene: identification of a new polymorphism associated with hypertension. <i>FEBS Letters</i> , 2003, 542, 27-31.	1.3	86
262	Independent Association of Fibrinogen with Carotid Intima-Media Thickness in Asymptomatic Subjects. <i>Cerebrovascular Diseases</i> , 2003, 16, 356-362.	0.8	28
263	Cardiomyocyte apoptosis in hypertensive cardiomyopathy. <i>Cardiovascular Research</i> , 2003, 59, 549-562.	1.8	110
264	Involvement of cardiomyocyte survival/apoptosis balance in hypertensive cardiac remodeling. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 293-307.	0.6	9
265	Clinical implications of apoptosis in hypertensive heart disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 284, H1495-H1506.	1.5	45
266	The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. <i>Journal of Hypertension</i> , 2003, 21, 2085-92.	0.3	21
267	Ultrasonic Backscatter and Serum Marker of Cardiac Fibrosis in Hypertensives. <i>Hypertension</i> , 2002, 39, 923-928.	1.3	68
268	Leptin Inhibits Angiotensin II-Induced Intracellular Calcium Increase and Vasoconstriction in the Rat Aorta. <i>Endocrinology</i> , 2002, 143, 3555-3560.	1.4	97
269	Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients. <i>Circulation</i> , 2002, 105, 2512-2517.	1.6	572
270	Stimulation of Cardiac Apoptosis in Essential Hypertension. <i>Hypertension</i> , 2002, 39, 75-80.	1.3	102

#	ARTICLE	IF	CITATIONS
271	Ultrasonic Backscatter and Diastolic Function in Hypertensive Patients. <i>Hypertension</i> , 2002, 40, 239-243.	1.3	28
272	Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2002, 20, 1855-1864.	0.3	107
273	Torsemide in chronic heart failure: results of the TORIC study. <i>European Journal of Heart Failure</i> , 2002, 4, 507-513.	2.9	215
274	Regulation of Myocardial Fibrillar Collagen by Angiotensin II. A Role in Hypertensive Heart Disease?. <i>Journal of Molecular and Cellular Cardiology</i> , 2002, 34, 1585-1593.	0.9	106
275	Corrigendum to "Torsemide in chronic heart failure: results of the TORIC study" [Eur. J. Heart Fail. 4 (2002) 507-513]. <i>European Journal of Heart Failure</i> , 2002, 4, 667-667.	2.9	3
276	Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases. <i>European Journal of Clinical Investigation</i> , 2002, 32, 291-294.	1.7	13
277	Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 149-160.	1.3	118
278	Effects of Antihypertensive Agents on the Left Ventricle. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 263-279.	1.0	20
279	A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. <i>Journal of Hypertension</i> , 2001, 19, 1871-1876.	0.3	76
280	Clinical aspects of hypertensive myocardial fibrosis. <i>Current Opinion in Cardiology</i> , 2001, 16, 328-335.	0.8	116
281	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. <i>American Journal of Cardiology</i> , 2001, 88, 1-20.	0.7	202
282	Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2-5.	0.4	46
283	The loop diuretic torsemide interferes with endothelin-1 actions in the aorta of hypertensive rats. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 18-21.	0.4	47
284	Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients. <i>Circulation</i> , 2001, 104, 286-291.	1.6	244
285	Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 14-17.	0.4	118
286	Biochemical Assessment of Myocardial Fibrosis in Hypertensive Heart Disease. <i>Hypertension</i> , 2001, 38, 1222-1226.	1.3	157
287	Vascular oxidant stress: Molecular mechanisms and pathophysiological implications. <i>Journal of Physiology and Biochemistry</i> , 2000, 56, 57-64.	1.3	101
288	Mechanisms of Increased Susceptibility to Angiotensin II-Induced Apoptosis in Ventricular Cardiomyocytes of Spontaneously Hypertensive Rats. <i>Hypertension</i> , 2000, 36, 1065-1071.	1.3	59

#	ARTICLE	IF	CITATIONS
289	Insulin-like growth factor I in essential hypertension. <i>Kidney International</i> , 1999, 55, 744-759.	2.6	28
290	Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 1999, 17, 107-114.	0.3	111
291	Decreased excretion of nitrate and nitrite in essential hypertensives with renal vasoconstriction. <i>Kidney International</i> , 1998, 54, S10-S13.	2.6	5
292	Apoptosis in hypertensive heart disease. <i>Current Opinion in Cardiology</i> , 1998, 13, 317-326.	0.8	64
293	Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension. <i>Journal of Hypertension</i> , 1998, 16, 863-870.	0.3	13
294	Is the tissue availability of circulating insulin-like growth factor I involved in organ damage and glucose regulation in hypertension?. <i>Journal of Hypertension</i> , 1997, 15, 1159-1165.	0.3	12
295	Angiotensin Converting Enzyme Inhibition Corrects Na ⁺ /H ⁺ Exchanger Overactivity in Essential Hypertension. <i>American Journal of Hypertension</i> , 1997, 10, 84-93.	1.0	24
296	Quinapril Inhibits c-Myc Expression and Normalizes Smooth Muscle Cell Proliferation in Spontaneously Hypertensive Rats. <i>American Journal of Hypertension</i> , 1997, 10, 1147-1152.	1.0	14
297	Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. <i>American Journal of Cardiology</i> , 1995, 76, 14D-17D.	0.7	15
298	Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats. <i>American Journal of Hypertension</i> , 1995, 8, 815-822.	1.0	44
299	Enhanced Na ⁺ -H ⁺ Exchanger Activity and NHE-1 mRNA Expression in Lymphocytes From Patients With Essential Hypertension. <i>Hypertension</i> , 1995, 25, 356-364.	1.3	21
300	Treatment With Lisinopril Normalizes Serum Concentrations of Procollagen Type III Amino-Terminal Peptide in Patients With Essential Hypertension. <i>American Journal of Hypertension</i> , 1994, 7, 52-58.	1.0	39
301	Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. <i>Hepatology</i> , 1994, 19, 1400-1406.	3.6	159
302	Current work in the cell biology of left ventricular hypertrophy. <i>Current Opinion in Cardiology</i> , 1994, 9, 512-519.	0.8	7
303	Abnormal expression of anion exchanger genes in primary biliary cirrhosis. <i>Gastroenterology</i> , 1993, 105, 572-578.	0.6	132
304	Elevated Levels of Parathyroid Hormone in Essential Hypertensive Patients With Increased Erythrocyte Potassium Efflux. <i>American Journal of Hypertension</i> , 1991, 4, 714-718.	1.0	2
305	Abnormal sympathetic and renal response to sodium restriction in compensated cirrhosis. <i>Gastroenterology</i> , 1991, 101, 1354-1360.	0.6	14
306	Uremia and Red Blood Cell Sodium Transport. <i>Nephron</i> , 1986, 43, 155-157.	0.9	9

#	ARTICLE	IF	CITATIONS
307	Intracerebroventricular Infusion of Sodium Chloride-Rich Artificial Cerebrospinal Fluid in Rats Induces Natriuresis and Releases An Inhibitor of Prostaglandin Synthesis. <i>Clinical Science</i> , 1984, 66, 621-624.	1.8	9
308	From cardiorenal syndromes to cardioneurology: a reflection of nephrologists on renocardiac syndromes. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	1.4	3